21.60
-0.1(-0.46%)
Currency In USD
| Previous Close | 21.7 |
| Open | 21.66 |
| Day High | 21.74 |
| Day Low | 21.34 |
| 52-Week High | 22.73 |
| 52-Week Low | 8.58 |
| Volume | 452,829 |
| Average Volume | 2.69M |
| Market Cap | 1.87B |
| PE | -6 |
| EPS | -3.6 |
| Moving Average 50 Days | 17.35 |
| Moving Average 200 Days | 13.64 |
| Change | -0.1 |
If you invested $1000 in Syndax Pharmaceuticals, Inc. (SNDX) since IPO date, it would be worth $1,800 as of December 25, 2025 at a share price of $21.6. Whereas If you bought $1000 worth of Syndax Pharmaceuticals, Inc. (SNDX) shares 5 years ago, it would be worth $895.52 as of December 25, 2025 at a share price of $21.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
GlobeNewswire Inc.
Dec 12, 2025 12:00 PM GMT
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) was named Best New Drug at the Scrip A
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
GlobeNewswire Inc.
Dec 08, 2025 11:50 AM GMT
– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts – – Retrospective review shows revumeni
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participat